• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by CG Oncology Inc.

    8/8/25 4:15:47 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGON alert in real time by email

    Unavailable

    Get the next $CGON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    8/19/2025$55.00Overweight
    Piper Sandler
    7/10/2025$40.00Buy
    Goldman
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    More analyst ratings

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on CG Oncology with a new price target

    Piper Sandler initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00

    8/19/25 8:33:40 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on CG Oncology with a new price target

    Goldman resumed coverage of CG Oncology with a rating of Buy and set a new price target of $40.00

    7/10/25 8:53:17 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on CG Oncology with a new price target

    Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

    5/2/25 8:14:21 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulay James exercised 22,686 shares at a strike of $1.82 and sold $884,909 worth of shares (22,686 units at $39.01) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/22/25 7:30:03 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $35,100 worth of shares (1,000 units at $35.10) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/16/25 4:15:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

    - Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent - IRVINE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced updated data on BOND-003 Cohort C showing 12 additional patients with high risk non-muscle

    9/5/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Completes Enrollment in PIVOT-006

    – Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveil

    9/3/25 8:00:39 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by CG Oncology Inc.

    SCHEDULE 13D - CG Oncology, Inc. (0001991792) (Subject)

    9/18/25 8:37:24 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    9/18/25 4:28:51 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    9/15/25 4:30:32 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

    4/A - CG Oncology, Inc. (0001991792) (Issuer)

    4/9/24 7:08:23 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $CGON
    Financials

    Live finance-specific insights

    View All

    CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

    - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

    4/26/25 4:10:03 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

    IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

    4/24/25 8:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

    3/28/25 7:00:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/12/24 2:30:47 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

    SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

    11/4/24 10:22:51 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CG Oncology Inc.

    SC 13G - CG Oncology, Inc. (0001991792) (Subject)

    7/22/24 4:35:57 PM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care